ClinicalTrials.gg
WithdrawnNCT01515826Updated Mar 26, 2014

VIGADEXA Gel Compared to VIGADEXA Solution Following Cataract Surgery

A Phase 3 interventional study of Moxifloxacin 0.5%/Dexamethasone Phosphate 0.075% Ophthalmic Gel (VIGADEXA Gel) and Moxifloxacin 0.5%/Dexamethasone Phosphate 0.1% Ophthalmic Solution (VIGADEXA Solution) in Cataracts, sponsored by Alcon Research. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-03-26.

Sponsored by Alcon Research (part of Alcon) · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Management decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing moxifloxacin in Cataract — 1 open to participants now, 1 under way, 1 of them phase 3. Moxifloxacin · Cataract.

Enrollment
12th of 12
0 · median 62
Started
2014
the only one that year
Phase 3
2 of 12
1 open now
Registered
7th of 12
by date
Lead sponsor
4 of 12
Alcon Research

Among the 12 studies testing moxifloxacin in Cataract, this one is the 12th largest by enrollment, is the only one that started in 2014, is one of 2 in phase 3, and was the 7th registered.

Cataract

1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.

Browse Cataract studies →

Open to participants now

1 of the 12 studies testing moxifloxacin in Cataract is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About moxifloxacin

Moxifloxacin: first FDA approval 1999 (AVELOX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing moxifloxacin in Cataract, or all of them as a file.
02

Study summary

The purpose of this study is to compare VIGADEXA (moxifloxacin 0.5%/dexamethasone phosphate 0.075%) ophthalmic gel to VIGADEXA (moxifloxacin 0.5%/dexamethasone phosphate 0.1%) ophthalmic solution in the prevention of postoperative inflammation and infection.

03

Conditions studied

  • Cataracts

Browse trials for

Keywords

  • Cataract surgery
  • Topical therapy
  • Prevention of inflammation
  • Inflammation of infection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older.
  • Diagnosis of cataract with intention to undergo routine, uncomplicated cataract surgery.
  • Able to understand and sign an form.
  • Other protocol-defined inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Glaucoma or ocular hypertension.
  • Use of topical or systemic non-steroidal anti-inflammatory drugs (NSAIDs) within 14 days prior to surgery or planned use during the study. Low-dose acetylsalicylic acid (up to 100 mg/day) is allowed.
  • Use of anti-bacterial, anti-viral, or anti-fungal agents or ocular medications within 30 days prior to enrollment in the study or during study, as specified by protocol.
  • Secondary implantation or replacement of the intra-ocular lens (IOL) in the study eye.
  • Planned use of contact lenses in the study eye during the study period.
  • Cataract surgery in the contralateral eye within 30 days prior to the Screening Visit, or planned for the 3 weeks after the cataract surgery in the study eye.
  • History of trauma to the study eye within the past 12 months.
  • Other protocol-defined exclusion criteria may apply.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    VIGADEXA Gel

    VIGADEXA ophthalmic gel topically administered TID to the operative eye starting the day before surgery, continuing on the day of surgery, and for 15 days following surgery.

    Drug: Moxifloxacin 0.5%/Dexamethasone Phosphate 0.075% Ophthalmic Gel (VIGADEXA Gel)

  • Active comparator
    VIGADEXA Solution

    VIGADEXA ophthalmic solution topically administered QID to the operative eye starting the day before surgery, continuing on the day of surgery, and for 15 days following surgery.

    Drug: Moxifloxacin 0.5%/Dexamethasone Phosphate 0.1% Ophthalmic Solution (VIGADEXA Solution)

Interventions

  • DrugMoxifloxacin 0.5%/Dexamethasone Phosphate 0.075% Ophthalmic Gel (VIGADEXA Gel)

    Drug page: Moxifloxacin

    One ribbon (approximately 1-1.5 cm) administered topically in the conjunctival sac of the study eye three times daily (TID), starting the day before surgery (Day -1) and continuing on the day of surgery and for 15 days following surgery.

    Also known as: FID 119149, VIGADEXA Gel

  • DrugMoxifloxacin 0.5%/Dexamethasone Phosphate 0.1% Ophthalmic Solution (VIGADEXA Solution)

    Drug page: Moxifloxacin

    One drop administered topically in the conjunctival sac of the study eye four times daily (QID), starting the day before surgery (Day -1) and continuing on the day of surgery and for 15 days following surgery.

    Also known as: VIGADEXA Solution

06

What researchers measure

Primary outcomes

  1. Percentage of patients with a score of 0 (<5 cells) for cells in the anterior chamber

    As assessed by the investigator during slit-lamp examination.

    Time frame: Day 15 post-operative

  2. Percentage of patients with no clinically evidenced bacterial infection

    As assessed by the investigator during slit-lamp examination.

    Time frame: Day 15 post-operative

Secondary outcomes

  1. Cells in the anterior chamber (study eye)

    As assessed by the investigator during slit-lamp examination.

    Time frame: Day 15 post-operative

  2. Ocular pain (study eye)

    As assessed by the investigator during patient interview.

    Time frame: Day 15 post-operative

  3. Inflammatory reaction (study eye)

    As assessed by the investigator during slit-lamp examination.

    Time frame: Day 15 post-operative

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2012
First posted
Jan 24, 2012
Start
Mar 2014
Primary completionEst.
Oct 2014
CompletionEst.
Oct 2014
Last update
Mar 26, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01515826
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Jan 24, 2012
Start date
Mar 2014
Primary completion
Oct 2014 (estimated)
Completion
Oct 2014 (estimated)
Last update
Mar 26, 2014

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Moxifloxacin

Start the discussion